Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Kadcyla | Trastuzumab emtansine | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kalydeco | Ivacaftor | Cystic fibrosis, R117H CFTR gating mutation | List with criteria/condition | Complete | ||
| Kalydeco | Ivacaftor | Cystic fibrosis, G551D mutation | List with criteria/condition | Complete | ||
| Kalydeco | Ivacaftor | Cystic Fibrosis, CFTR gating mutations | List with criteria/condition | Complete | ||
| Kanuma | sebelipase alfa | Lysosomal acid lipase deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kazano | Alogliptin plus metformin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Kerendia | finerenone | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kesimpta | ofatumumab | Multiple Sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kevzara | sarilumab | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | Nonsquamous NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | Melanoma Adjuvant Treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Classical Hodgkin lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | Advanced non-small cell lung carcinoma (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Unresectable or metastatic MSI-H or dMMR solid tumors | Pending | |||
| Keytruda | pembrolizumab | Non-small cell lung cancer (NSCLC) | Pending | |||
| Keytruda | pembrolizumab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | |||
| Keytruda | Pembrolizumab | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Keytruda | Pembrolizumab | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Renal cell carcinoma, adjuvant | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Melanoma Adjuvant Treatment | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024